MK-2461
MK-2461 is an investigational small molecule inhibitor that targets the c-Met receptor tyrosine kinase. It is being studied for its potential use in the treatment of various types of cancer, particularly those that exhibit overexpression or dysregulation of the c-Met pathway.
Mechanism of Action[edit | edit source]
MK-2461 functions by inhibiting the activity of the c-Met receptor, a protein that plays a critical role in cell signaling pathways involved in cell proliferation, survival, and metastasis. The c-Met receptor is activated by its ligand, hepatocyte growth factor (HGF), leading to downstream signaling that can promote oncogenic processes. By inhibiting c-Met, MK-2461 aims to disrupt these pathways, thereby inhibiting tumor growth and spread.
Clinical Development[edit | edit source]
MK-2461 is currently in the investigational stage and has been evaluated in preclinical studies and early-phase clinical trials. These studies aim to assess its safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with advanced solid tumors. The results from these studies will determine the potential of MK-2461 to proceed to later-stage clinical trials.
Potential Indications[edit | edit source]
The primary focus of MK-2461's development is in the treatment of cancers that are driven by aberrant c-Met signaling. This includes certain types of lung cancer, gastric cancer, and renal cell carcinoma, among others. The identification of patients with tumors that have c-Met amplification or mutations may help in selecting those who are most likely to benefit from MK-2461 therapy.
Challenges and Considerations[edit | edit source]
One of the challenges in developing c-Met inhibitors like MK-2461 is the complexity of the c-Met signaling network and its interaction with other pathways. Resistance mechanisms, such as compensatory activation of alternative pathways, may limit the effectiveness of c-Met inhibitors. Combination therapies that target multiple pathways are being explored to overcome these challenges.
Also see[edit | edit source]
Template:Receptor tyrosine kinase inhibitors
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
